Mixed trend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend up since Sep 30 · inside the Ichimoku cloud · RSI 50 · MACD below its signal
| 2.15 | 52-week high | +104.76% |
| 1.20 | Previous week high | +14.29% |
| 1.16 | R3 (classic) | +10.48% |
| 1.14 | Previous month high | +8.57% |
| 1.13 | R2 (classic) | +7.62% |
| 1.10 | Previous day high | +4.76% |
| 1.09 | R1 (classic) | +3.81% |
| 1.06 | Pivot | +0.95% |
| 1.05 | Price now | |
| 1.03 | Previous day low | −1.90% |
| 1.02 | Previous week low | −2.86% |
| 1.02 | S1 (classic) | −2.86% |
| 0.9900 | S2 (classic) | −5.71% |
| 0.9500 | S3 (classic) | −9.52% |
| 0.7600 | Previous month low | −27.62% |
| 0.7600 | 52-week low | −27.62% |
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $16.8K | 0.00% | 13.10K | New | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a TLSA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 13, 2026 | Elrifi IvorChief Executive Officer | — | 1.05M | — |
| Aug 4, 2026 | Elrifi IvorChief Executive Officer | Purchase at price 0.97 - 1.00 per share. | 321.4K | $318.91K |
| Aug 2, 2026 | Elrifi IvorChief Executive Officer | Purchase at price 1.00 per share. | 667K | $667.00K |
| Jul 20, 2026 | Cerrone Gabriele MDirector and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) at price 0.99 per share. | 42.4K | $41.93K |
| Jul 20, 2026 | Cerrone Gabriele MDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 0.99 per share. | 42.4K | $41.93K |
| Jun 11, 2026 | Cerrone Gabriele MDirector and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) at price 1.11 per share. | 15K | $16.65K |
| Jun 11, 2026 | Cerrone Gabriele MDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 1.11 per share. | 15K | $16.65K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 1.3 | -4.0 | -19.3 | 9.4 | 10.2 | -9.2 | -19.5 | -3.9 | 12.1 | -5.4 | −29.5% | ||
| 2025 | -1.4 | 87.0 | -16.3 | 25.9 | 0.0 | 16.2 | 58.2 | -27.6 | 19.3 | -11.1 | -6.3 | -17.2 | +112.9% |
| 2024 | -5.4 | -9.4 | -6.3 | 46.7 | 51.5 | -8.0 | 16.3 | -6.5 | -4.0 | 2.1 | -3.1 | -26.3 | +25.0% |
| 2023 | 8.3 | -13.8 | 94.6 | -27.5 | 7.6 | -20.0 | -4.4 | 12.3 | -9.6 | -1.5 | -9.2 | -5.1 | −6.7% |
| 2022 | -13.5 | -21.7 | 61.5 | -2.9 | -35.3 | 13.6 | -2.7 | 4.1 | 2.6 | -10.3 | -5.7 | -9.1 | −37.5% |
| 2021 | 82.2 | -18.2 | -8.0 | -5.8 | -10.0 | 0.0 | -9.4 | -22.1 | -12.0 | 6.8 | -19.2 | -23.8 | −52.5% |
| 2020 | -11.9 | -10.1 | -4.7 | 35.8 | 138.6 | -2.9 | 172.1 | -49.5 | -5.7 | 14.7 | -34.8 | -18.9 | +87.0% |
| 2019 | -9.4 | -11.4 | 1.2 | 36.4 | -14.8 | 2.4 | -2.4 | -10.7 | -1.9 | -0.6 | -11.8 | 0.0 | −27.5% |
| 2018 | -5.1 | −5.1% |
TimeframesDown on the weekly, mixed on the hourly, daily and monthly.
bouncing over the 21 EMA
pulling back under the 21 EMA
under a falling 21 EMA, 21 under 50
pulling back under the 21 EMA
Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases. The company is headquartered in London, the United Kingdom.
Buy / hold / sell counts